This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
FDA Amends Hologic's Aptima's EUA for Asymptomatic Testing
by Zacks Equity Research
The FDA's modified EUA for Hologic's (HOLX) Aptima SARS-CoV-2 assay includes testing of asymptomatic individuals and symptomatic pooling protocol to curb the spread of coronavirus.
Coronavirus Drives Testing Stocks: Is There Room for More Upside?
by Urmimala Biswas
Given the current testing requirements across the world, the diagnostic testing business for COVID-19 is rapidly evolving.
Masimo's (MASI) Rad-G Pulse Oximeter Receives FDA Clearance
by Zacks Equity Research
Masimo's (MASI) Rad-G Pulse Oximeter receives FDA clearance, thereby allowing clinicians to access the most accurate and reliable pulse oximetry monitoring technologies.
Here's Why You Should Hold on to Hologic (HOLX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Hologic (HOLX) on robust growth of the Diagnostics segment and regulatory approvals.
Hologic (HOLX) Receives EUA for Asymptomatic Coronavirus Testing
by Zacks Equity Research
The FDA approves Hologic's (HOLX) Panther Fusion SARS-CoV-2 assay and pooling protocol to curb the unrelenting spread of coronavirus.
Medtronic, Axonics Patent War Continues for Sacral Neuromodulation (Revised)
by Zacks Equity Research
Medtronic's (MDT) InterStim system electrically stimulates the sacral nerves.
Syneos Health Banks on Essential Therapies Amid Coronavirus Woe
by Zacks Equity Research
Syneos Health's (SYNH) over 70% of clinical businesses comprise essential therapeutic areas that are experiencing reduced impacts of coronavirus outbreak.
Medtronic Wins Neuromodulation Patent Dispute Against Axonics
by Zacks Equity Research
Medtronic's (MDT) InterStim system electrically stimulates the sacral nerves.
Here's Why You Should Hold on to Hill-Rom (HRC) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Hill-Rom (HRC) on product launches as well as solid third-quarter of fiscal 2020 results.
Quest Diagnostics Partners in Pilot Program for COVID-19 Test
by Zacks Equity Research
Quest Diagnostics (DGX) to provide online test results for COVID-19 samples collected via drone-delivered at-home self-collection kits as part of a pilot program.
NuVasive Banks on Product Launches Amid Procedural Volume Loss
by Zacks Equity Research
NuVasive (NUVA) is leaving no stone unturned to capture the fast-growing spine market.
Boston Scientific, Farapulse Sign Deal for Treatment of AF
by Zacks Equity Research
Boston Scientific (BSX) aims to provide a comprehensive portfolio of electrophysiology products and services via the latest investment agreement.
Alphatec (ATEC) Looks Good: Stock Adds 5.8% in Session
by Zacks Equity Research
Alphatec (ATEC) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Zacks.com featured highlights include: ATVI, EAT, HOLX, LEN and SPWR
by Zacks Equity Research
Zacks.com featured highlights include: ATVI, EAT, HOLX, LEN and SPWR
Abbott's MitraClip G4 Receives CE Mark for Treatment of MR
by Zacks Equity Research
Abbott's (ABT) MitraClip G4 is expected to improve MR patients' quality of life post its usage eligibility in Europe and other countries recognizing the CE Mark.
LabCorp Boosts Oncology Offerings With Resolution ctDx Launch
by Zacks Equity Research
This development comes on the heels of LabCorp's (LH) commercial partnership with non-invasive liquid biopsy platform developer, Resolution Bioscience.
Tap 5 Top Stocks With Strong Earnings Beat Prospects
by Sanghamitra Saha
Invest in top-ranked stocks that are likely to beat earnings estimates in the upcoming release.
Quest Diagnostics New Tests Uptake Strong Amid Coronavirus Woe
by Zacks Equity Research
Heavy demand for COVID-19 molecular testing helps partially offset the base volume decline for Quest Diagnostics (DGX).
Medtronic TYRX Driveline Gets FDA's Breakthrough Designation
by Zacks Equity Research
This development helps Medtronic (MDT) to augment its research work in the space of interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be positive about ResMed (RMD) owing to its robust product line and consistent high demand for its critical care products.
Pacific Biosciences (PACB) Looks Good: Stock Adds 5.3% in Session
by Zacks Equity Research
Pacific Biosciences (PACB) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
The Zacks Analyst Blog Highlights: FMS, HOLX and TMO
by Zacks Equity Research
The Zacks Analyst Blog Highlights: FMS, HOLX and TMO
Insulet's Omnipod DASH Shines, New Omnipod Uptake Slows Down
by Zacks Equity Research
Insulet (PODD) adds significant capacity in preparation of the Omnipod 5 launch in 2021.
Abbott Launches Sports Biosensor in Europe, Boosts CGM Wing
by Zacks Equity Research
Abbott (ABT) makes its first non-exclusive collaboration with Atlanta-based sports technology company, Supersapiens.
STERIS (STE) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
STERIS (STE) is optimistic about maintaining growth momentum on broader product and service portfolio along with strength in its Life Sciences business.